0
0
May 9, 2026
WASHINGTON — President Donald Trump has reportedly signed off on a plan to dismiss Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, marking a potential climax to a year defined by internal agency friction, high-profile staff departures, and intense political pressure from both the pharmaceutical industry and social conservative groups.
The development, first reported by The Wall Street Journal on May 8, 2026, suggests that while a final decision has not been formally announced, the administration is moving toward a leadership change at the helm of the $7.2 billion agency. The reported plan arrives as the FDA faces a “vacuum” of experience, with several key drug divisions currently led by acting directors following an exodus of veteran regulators.
A Tenure Defined by “Blind Spots” and Bold Moves
Dr. Marty Makary, a renowned Johns Hopkins surgeon and author of the bestseller Blind Spots, took office in March 2025 with a mandate to modernize the FDA and challenge “medical groupthink.” His tenure was initially hailed by supporters of the “Make America Healthy Again” (MAHA) movement, led by HHS Secretary Robert F. Kennedy Jr., for its focus on transparency and faster access to innovative therapies.
During his 14 months in office, Makary implemented several sweeping reforms:
-
The Commissioner’s National Priority Voucher (CNPV): A controversial program designed to grant expedited reviews to hand-selected therapies.
-
Transparency Initiatives: Proactively publishing Complete Response Letters (CRLs)—documents explaining why a drug was rejected—which were previously kept confidential between the FDA and manufacturers.
-
Efficiency Drives: Reducing the default requirement for drug approvals from two pivotal trials to one in specific cases.
However, these reforms often placed him at odds with the agency’s professional staff. Dr. Richard Pazdur, the long-time head of the FDA’s Oncology Center of Excellence, resigned in December 2025, reportedly citing concerns that the “wall” between the commissioner’s political office and independent scientific review staff had been breached.
Friction with the White House and Industry
Despite his alignment with the administration’s deregulatory goals, Makary’s relationship with President Trump reportedly soured over specific policy “flashpoints.”
Sources familiar with the matter indicate that Trump was particularly incensed by the FDA’s handling of fruit-flavored e-cigarettes. While Trump had pledged to protect the vaping industry during his 2024 campaign, the FDA under Makary resisted approving certain flavored products, leading to a direct rebuke from the President.
Additionally, the pharmaceutical industry—a critical stakeholder—expressed mounting frustration over “unpredictable” rejections. Recent rejections of high-profile therapies for advanced melanoma and Duchenne muscular dystrophy led to significant market volatility. On news of Makary’s potential ouster, shares of Replimune, whose melanoma therapy was twice rejected by the agency, surged nearly 22%.
The Abortion Medication Conflict
Perhaps the most significant pressure on Makary came from social conservative allies. Anti-abortion groups, including Susan B. Anthony Pro-Life America, have vocally criticized the Commissioner for what they perceive as a failure to restrict access to mifepristone, the medication used in more than 60% of U.S. abortions.
While Makary had promised a safety review of the drug during his confirmation hearings, the slow pace of that review led to accusations of political foot-dragging. On the day the firing reports emerged, White House officials were scheduled to meet with activists who have labeled Makary’s leadership as “unacceptable.”
Expert Perspectives: A “Leadership Carousel”
Public health experts warn that the potential firing could exacerbate an existing crisis of morale and expertise within the agency.
“Frequent leadership changes erode institutional knowledge and could delay critical drug approvals,” says Dr. Jesse Goodman, former FDA Chief Scientist. “There is a vacuum right now that has created significant gaps in experience at the highest levels of drug regulation.”
The agency has already seen a historic turnover rate. Dr. Vinay Prasad, the former head of the Center for Biologics Evaluation and Research (CBER), departed the agency for the second time in April 2026 following disputes over gene therapy trials for Huntington’s disease. His exit left CBER—the division responsible for vaccines and gene therapies—under its fifth leader in less than 18 months.
Conversely, some advocates for reform argue a change is necessary. Dr. Mark Hyman, a functional medicine advocate, has previously suggested that the agency needs a leader who can more aggressively pivot toward the MAHA agenda, including stricter regulations on food dyes and a complete overhaul of the American food supply.
What This Means for Public Health
For the average American, the stability of the FDA is not just a political matter; it affects the safety and availability of the food and medicine they use every day.
| Aspect | Potential Impact of Leadership Change |
| Drug Approvals | Possible delays in cancer and rare disease therapies as acting heads prioritize backlogs. |
| Abortion Access | Potential for stricter “in-person” dispensing rules for mifepristone if a more conservative successor is named. |
| Industry Stability | Potential return to “predictability” for biotech investors, though initial volatility is likely. |
| Vaccine Policy | Uncertain future for fall COVID-19 boosters and mRNA flu vaccine approvals. |
Looking Ahead
As of May 9, the White House has not named a formal successor, though names like former FDA Commissioner Stephen Hahn and former Assistant Health Secretary Brett Giroir have surfaced in reports.
For now, the FDA remains in a state of “limbo.” While the agency’s core functions—inspecting food and reviewing life-saving drugs—continue, the strategic direction of U.S. healthcare regulation hangs in the balance.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Wall Street Journal. “Trump Poised to Ax FDA Commissioner.” Reported May 8, 2026.
